AYTU BioPharma
AYTU
24 hedge funds and large institutions have $4.81M invested in AYTU BioPharma in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 3 closing their positions.
1.1% less ownership
Funds ownership: 34.4% → 33.31% (-1.1%)
11% less funds holding
Funds holding: 27 → 24 (-3)
20% less capital invested
Capital invested by funds: $5.99M → $4.81M (-$1.18M)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Stonepine Capital Management
Bend,
Oregon
|
+$73.8K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$23.8K |
| 3 |
Renaissance Technologies
New York
|
+$1.55K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$16 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$63.5K |
| 2 |
AC
Armistice Capital
New York
|
-$41.4K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$10K |
| 4 |
Dimensional Fund Advisors
Austin,
Texas
|
-$4.45K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$1.27K |
AYTU Hedge Fund Activity: Q3 2024 in Review
24 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in AYTU BioPharma (AYTU) for Q3 2024, worth a combined $4.81M — down 20% from $5.99M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of AYTU and 0 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 4 added.
The largest buyer was Stonepine Capital Management, adding an estimated $73.8K. The largest seller was Citadel Advisors, exiting entirely with an estimated $63.5K sold.
- 24 institutional investors held AYTU BioPharma (AYTU) as of Q3 2024, down from 27 in Q2 2024.
- Funds reported $4.81M of AYTU BioPharma stock for Q3 2024, down 20% quarter-over-quarter.
- 0 funds opened new AYTU BioPharma positions in Q3 2024 and 3 closed out, a net change of -3 holders.
- The largest AYTU BioPharma buyer in Q3 2024 was Stonepine Capital Management, an estimated $73.8K added.
- The largest AYTU BioPharma seller in Q3 2024 was Citadel Advisors, an estimated $63.5K sold.
Based on aggregated 13F filings for Q3 2024.